Managing agitation and difficult behavior in dementia.

The dementias are associated with disruptions in cognition, function, and behavior. Before the advent of dementia-specific therapies, management of difficult behaviors was the primary ‘‘treatment’’ of demented persons. Problematic behavioral symptoms such as agitation, apathy, depression, anxiety, delusions, irritability, and disinhibition are highly prevalent during the course of dementia [1]. Agitation and difficult behaviors are important factors influencing a family’s decision to choose nursing home placement for their demented elder [2]. Agitation occurs in as many as 70% to 90% of demented elderly nursing home patients, perhaps 50% of whom become frankly aggressive [3]. The term ‘‘agitation’’ describes inappropriate verbal, vocal, or motor activity that does not result from need. The agitated behaviors do not serve the interest of the patient and adversely affect others’ efforts to help. Some behaviors are inherently inappropriate, whereas others may be inappropriate due to their intensity, frequency, or the context in which they are exhibited [4]. Increasingly, the term ‘‘behavioral and psychological symptoms of dementia’’ is used for clinical purposes to group the myriad agitated and difficult behaviors arising in demented patients [5].

[1]  N. Herrmann,et al.  Donepezil for behavioural disorders associated with Lewy bodies: a case series , 2000, International journal of geriatric psychiatry.

[2]  J. Edinger,et al.  Reversible parkinsonism and cognitive impairment with chronic valproate use , 1996, Neurology.

[3]  C. Cooney,et al.  Use of drugs by Old Age Psychiatrists in the treatment of psychotic and behavioural symptoms in patients with dementia , 2001, Aging & mental health.

[4]  R. Baker,et al.  Effectiveness of Rapid Initial Dose Escalation of up to Forty Milligrams per Day of Oral Olanzapine in Acute Agitation , 2003, Journal of clinical psychopharmacology.

[5]  A. Schatzberg,et al.  Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. , 2002, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[6]  L. Schneider,et al.  A Metaanalysis of Controlled Trials of Neuroleptic Treatment in Dementia , 1990, Journal of the American Geriatrics Society.

[7]  H. Brodaty,et al.  Psychosis, depression and behavioural disturbances in Sydney nursing home residents: prevalence and predictors , 2001, International journal of geriatric psychiatry.

[8]  P. Tariot,et al.  Treatment of agitation in dementia. , 1997, The Journal of clinical psychiatry.

[9]  A. LaCroix,et al.  Exercise plus behavioral management in patients with Alzheimer disease: a randomized controlled trial. , 2003, JAMA.

[10]  J. Cohen-Mansfield,et al.  Assessment of Agitation , 1996, International Psychogeriatrics.

[11]  N L Foster,et al.  Treatment of agitation in AD , 2000, Neurology.

[12]  D. Jeste,et al.  Psychosis of Alzheimer's disease and related dementias. Diagnostic criteria for a distinct syndrome. , 2000, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[13]  P. Tariot,et al.  Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. , 1998, The American journal of psychiatry.

[14]  R. Hales,et al.  J Neuropsychiatry Clin Neurosci , 1992 .

[15]  B. Svarstad,et al.  Challenges to the use of nonpharmacologic interventions in nursing homes. , 2002, Psychiatric services.

[16]  S. Tunis,et al.  Assessing antipsychotic effectiveness in dementia with the factor structure of the Psychogeriatric Dependency Rating Scale (PGDRS). , 2003, Journal of the American Medical Directors Association.

[17]  B. Oken Practice parameter: Management of dementia (an evidence-based review) , 2001, Neurology.

[18]  P. Tariot,et al.  Mood stabilizers in Alzheimer's disease: symptomatic and neuroprotective rationales. , 2002, Advanced drug delivery reviews.

[19]  D. Sultzer,et al.  A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. , 1997, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[20]  A W Toga,et al.  Orbital and dorsolateral frontal perfusion defect associated with behavioral response to cholinesterase inhibitor therapy in Alzheimer's disease. , 2000, The Journal of neuropsychiatry and clinical neurosciences.

[21]  L. Schneider,et al.  Psychosis of Alzheimer disease: validity of the construct and response to risperidone. , 2003, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[22]  B. Pollock,et al.  Selective Serotonin Reuptake Inhibitors for Late-Life Depression , 2001, Drugs & aging.

[23]  D. Jeste,et al.  Pharmacological Treatment of Psychosis and Agitation in Elderly Patients with Dementia , 2002 .

[24]  C. Wolfson,et al.  Factors associated with long-term institutionalization of older people with dementia: data from the Canadian Study of Health and Aging. , 2001, The journals of gerontology. Series A, Biological sciences and medical sciences.

[25]  M. Freedman,et al.  Relationship of psychosis to aggression, apathy and function in dementia , 2001, International journal of geriatric psychiatry.

[26]  S. McPherson,et al.  Neuropsychiatric assessment of Alzheimer’s disease and related dementias , 2001, Aging.

[27]  G A Chase,et al.  Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. , 1990, The American journal of psychiatry.

[28]  D. Aarsland,et al.  Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia , 2003, International journal of geriatric psychiatry.

[29]  L. Miller Gabapentin for Treatment of Behavioral and Psychological Symptoms of Dementia , 2001, The Annals of pharmacotherapy.

[30]  H. Sackeim,et al.  A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease. , 1998, The American journal of psychiatry.

[31]  M. Raji,et al.  Mirtazapine for Treatment of Depression and Comorbidities in Alzheimer Disease , 2001, The Annals of pharmacotherapy.

[32]  R. Petersen,et al.  A collaborative study of the emergence and clinical features of the major depressive syndrome of Alzheimer's disease. , 2003, The American journal of psychiatry.

[33]  Kristine Yaffe,et al.  Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. , 2003, JAMA.

[34]  S H Ferris,et al.  A family intervention to delay nursing home placement of patients with Alzheimer disease. A randomized controlled trial. , 1996, JAMA.

[35]  J. Yesavage,et al.  How Well Are Clinicians Following Dementia Practice Guidelines? , 2002, Alzheimer disease and associated disorders.

[36]  P. Tariot,et al.  Valproate therapy for agitation in dementia: open-label extension of a double-blind trial. , 2003, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[37]  G. Grossberg The ABC of Alzheimer's Disease: Behavioral Symptoms and Their Treatment , 2002, International Psychogeriatrics.

[38]  M. Mega,et al.  The Neuropsychiatric Inventory , 1994, Neurology.

[39]  A. C. Stein,et al.  Practice parameter: Risk of driving and Alzheimer’s disease (an evidence-based review) , 2000, Neurology.

[40]  Charles M Beasley,et al.  Comparison of Rapidly Acting Intramuscular Olanzapine, Lorazepam, and Placebo: A Double-blind, Randomized Study in Acutely Agitated Patients with Dementia , 2002, Neuropsychopharmacology.

[41]  D. Christensen,et al.  Alprazolam as an Alternative to Low‐Dose Haloperidol in Older, Cognitively Impaired Nursing Facility Patients , 1998, Journal of the American Geriatrics Society.

[42]  C. Salzman Treatment of the agitation of late-life psychosis and Alzheimer’s disease , 2001, European Psychiatry.

[43]  J. Friedman,et al.  Long‐term outcome of quetiapine use for psychosis among parkinsonian patients , 2003, Movement disorders : official journal of the Movement Disorder Society.

[44]  S. Edland,et al.  Prevalence and incidence of major depression in Alzheimer's disease. , 1994, The American journal of psychiatry.

[45]  D. Sultzer,et al.  Does Behavioral Improvement with Haloperidol or Trazodone Treatment Depend on Psychosis or Mood Symptoms in Patients with Dementia? , 2001, Journal of the American Geriatrics Society.

[46]  Jacob Gordon,et al.  Clozapine in Parkinson's Disease Psychosis: 5-Year Follow-up Review , 2003, Clinical neuropharmacology.

[47]  H. Khouzam Capgras syndrome responding to the antidepressant mirtazapine , 2002, Comprehensive therapy.

[48]  D. Jeste,et al.  Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. , 1999, The Journal of clinical psychiatry.

[49]  O. Zanetti,et al.  Memory rehabilitation in Alzheimer's disease: a review of progress , 2001, International journal of geriatric psychiatry.

[50]  R. Tamura,et al.  Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. , 2000, Archives of general psychiatry.

[51]  N. Herrmann Recommendations for the Management of Behavioral and Psychological Symptoms of Dementia , 2001, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[52]  J. Yesavage,et al.  A retrospective chart review of gabapentin for the treatment of aggressive and agitated behavior in patients with dementias. , 2000, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[53]  R. van Reekum,et al.  Gender, aggression and serotonergic function are associated with response to sertraline for behavioral disturbances in Alzheimer's disease , 2002, International journal of geriatric psychiatry.

[54]  J. Cohen-Mansfield,et al.  A description of agitation in a nursing home. , 1989, Journal of gerontology.

[55]  V. Lerner,et al.  Donepezil as Add-on Treatment of Psychotic Symptoms in Patients with Dementia of the Alzheimer's Type , 2003, Clinical neuropharmacology.

[56]  G. Miremont-Salamé,et al.  Benzodiazepine utilization patterns in Alzheimer's disease patients , 2003, Pharmacoepidemiology and drug safety.

[57]  S H Ferris,et al.  Assessing Patterns of Agitation in Alzheimer's Disease Patients with the Cohen‐Mansfield Agitation Inventory , 1997, Alzheimer disease and associated disorders.

[58]  S. Finkel,et al.  Behavioral and psychological symptoms of dementia: a current focus for clinicians, researchers, and caregivers. , 2001, The Journal of clinical psychiatry.

[59]  M. Denke,et al.  Intramuscular medroxyprogesterone acetate for sexual aggression in elderly men , 1992, The Lancet.

[60]  B. Pollock,et al.  Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. , 2002, The American journal of psychiatry.

[61]  L. Thal,et al.  No Long-Term Effect of Behavioral Treatment on Psychotropic Drug Use for Agitation in Alzheimer's Disease Patients , 2002, Journal of geriatric psychiatry and neurology.

[62]  P. Roy-Byrne,et al.  Assessment and Treatment of Nursing Home Residents with Depression or Behavioral Symptoms Associated with Dementia: A Review of the Literature , 2003, Journal of the American Geriatrics Society.

[63]  D. Paleacu,et al.  Donepezil for the Treatment of Behavioral Symptoms in Patients With Alzheimer's Disease , 2002, Clinical neuropharmacology.

[64]  D. Scharre,et al.  Cognitive and Behavioral Effects of Quetiapine in Alzheimer Disease Patients , 2002, Alzheimer disease and associated disorders.

[65]  M. Mega,et al.  The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease. , 1999, Archives of neurology.

[66]  M. Weiner,et al.  Balancing psychosocial and psychopharmacologic measures in Alzheimer's disease , 1994 .

[67]  Cooper Aj Medroxyprogesterone acetate (MPA) treatment of sexual acting out in men suffering from dementia. , 1987 .

[68]  H. Higuchi,et al.  Quetiapine treatment of psychotic symptoms and aggressive behavior in patients with dementia with Lewy bodies: A case series , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[69]  R. Reeves,et al.  Orally disintegrating olanzapine for the treatment of psychotic and behavioral disturbances associated with dementia. , 2003, Southern medical journal.

[70]  Jeffrey L. Cummings,et al.  Practice parameter: Diagnosis of dementia (an evidence-based review) Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2001 .

[71]  B. Vaccaro,et al.  Clozapine in Older Patients With Psychosis and Behavioral Disruption. , 1995, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.